Published in Vaccine Weekly, September 4th, 1995
The genetically engineered vaccine induces "killer" T cells - in addition to anti-HIV antibodies - that should be more effective against the constantly changing HIV, said Dr. Paul Spearman, assistant professor of Pediatrics and principal investigator in the trial.
The novel vaccine is called p17/p24:Ty-VLP.
"I would like to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.